COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced today that it has achieved a $1 million milestone payment from its Japanese commercial partner, JCR Pharmaceuticals, for development progress made advancing Prochymal for the treatment of acute graft vs. host disease (GvHD) in Japan.
